Latest Biotech News

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

AdAlta Limited has fully repaid its remaining NLSC investment in cash, ending its obligation to issue further shares and positioning itself for private capital raises to advance its CAR-T therapies.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.

Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.